TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
NYSE · SEC CIK 818686 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $113.29M 46 sales by 14 insiders
- Filings on record
- 314 since 2021-08-12, latest 2026-09-22 17:01
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Francis Richard D | Pres, CEO | — | $31.26M |
| MIGNONE ROBERTO | Dir | — | $22.82M |
| Kalif Eliyahu Sharon | EVP, CFO | — | $20.72M |
| Sabag Mark | See "Remarks" | — | $13.15M |
| Daniell Richard | EVP, European Commercial | — | $12.08M |
| Hughes Eric A | See "Remarks" | — | $4.17M |
| Fox Christine | EVP, U.S. Commercial | — | $2.75M |
| Lippman Evan | EVP, Business Development | — | $2.16M |
| Weiss Amir | CAO | — | $1.41M |
| Shields Matthew | EVP, Gbl Ops | — | $1.40M |
Transactions 305
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-10 | 2022-02-09 | TEVA | Daniell Richard | EVP, European Commercial | S - Sale+OE | $9.06 | -13.1K | 20.3K | -39% | -$119.0K |
| D | 2022-02-10 | 2022-02-09 | TEVA | Stark David Matthew | EVP CLO | S - Sale+OE | $9.06 | -6,110 | 9,402 | -39% | -$55.4K |
| D | 2022-02-10 | 2022-02-09 | TEVA | Stark David Matthew | EVP CLO | M - OptEx | — | +12.5K | 15.5K | +422% | — |
| D | 2021-11-03 | 2021-11-01 | TEVA | Schultz Kare | Pres, CEO, Dir | M - OptEx | — | +180.0K | 1.04M | +21% | — |
| 2021-08-12 | 2021-08-10 | TEVA | Fridriksdottir Hafrun | Executive VP, Gbl R, D | S - Sale | $9.95 | -50.9K | 41.4K | -55% | -$506.1K |
Purchase Sale Sale after option exercise All abbreviations